Pfizer’s ABRYSVO Shows Promise as RSV Vaccine for At-Risk Adults: Phase 3 Study Results
Pfizer's announcement of positive trial results for its RSV vaccine, Abrysvo, in high-risk adults under 60 led to a 3%...
Stay informed with our financial updates, stocks, bonds, commodities. Get global & political insights. Follow us & enable notifications for the latest updates.